fasudil has been researched along with Abnormality, Heart in 5 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The optimal dose of Fasudil is still controversial in congenital heart disease accompanied with severe pulmonary hypertension (CHD-PAH)." | 5.30 | The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension. ( Liu, R; Ruan, H; Yang, X; Zhang, Y, 2019) |
| "This study aimed to determine whether the Rho-kinase-mediated pathway is involved in the pathogenesis of left-to-right shunt-induced pulmonary hypertension and whether fasudil exhibits acute beneficial effects on the hemodynamics of these patients." | 3.75 | Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease. ( Li, F; Sun, R; Xia, W; Yuan, S, 2009) |
| "Fasudil was well tolerated in patients with CHD and severe PAH, and significantly reduced PAP and PVR without affecting CI, SAP or SaO2." | 1.42 | Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects. ( Chen, HY; Cui, CS; Meng, LL; Wang, QG; Xiao, JW; Zhang, DZ; Zhang, P; Zhu, XY, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ruan, HY | 1 |
| Zhang, YG | 1 |
| Liu, R | 2 |
| Ruan, H | 1 |
| Zhang, Y | 1 |
| Yang, X | 1 |
| Xiao, JW | 1 |
| Zhu, XY | 1 |
| Wang, QG | 1 |
| Zhang, DZ | 1 |
| Cui, CS | 1 |
| Zhang, P | 1 |
| Chen, HY | 1 |
| Meng, LL | 1 |
| Odagiri, K | 1 |
| Watanabe, H | 1 |
| Li, F | 1 |
| Xia, W | 1 |
| Yuan, S | 1 |
| Sun, R | 1 |
2 trials available for fasudil and Abnormality, Heart
| Article | Year |
|---|---|
[Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adult; Familial Primary Pulmonary Hypertension; Heart | 2018 |
The acute effects of 30 mg vs 60 mg of intravenous Fasudil on patients with congenital heart defects and severe pulmonary arterial hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Blood Pressure; Cardiac Catheteriz | 2019 |
3 other studies available for fasudil and Abnormality, Heart
| Article | Year |
|---|---|
Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Cardiac Catheterization; Female; H | 2015 |
Effects of the Rho-kinase inhibitor, fasudil, on pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Female; Heart Defects, Congenital; Hemodynamics; Huma | 2015 |
Acute inhibition of Rho-kinase attenuates pulmonary hypertension in patients with congenital heart disease.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Child; Female; Follow-Up Studies; Heart D | 2009 |